Literature DB >> 17108044

Tumor necrosis factor (TNF) protects resistant C57BL/6 mice against herpes simplex virus-induced encephalitis independently of signaling via TNF receptor 1 or 2.

Patric Lundberg1, Paula V Welander, Carl K Edwards, Nico van Rooijen, Edouard Cantin.   

Abstract

Tumor necrosis factor (TNF) is a multifunctional cytokine that has a role in induction and regulation of host innate and adaptive immune responses. The importance of TNF antiviral mechanisms is reflected by the diverse strategies adopted by different viruses, particularly members of the herpesvirus family, to block TNF responses. TNF binds and signals through two receptors, Tnfrsf1a (TNF receptor 1 [TNFR1], or p55) and Tnfrsf1b (TNFR2, or p75). We report here that herpes simplex virus 1 (HSV-1) infection of TNF-/- mice on the resistant C57BL/6 genetic background results in significantly increased susceptibility (P < 0.0001, log rank test) to fatal HSV encephalitis (HSE) and prolonged persistence of elevated levels of virus in neural tissues. In contrast, although virus titers in neural tissues of p55-/- N13 mice were elevated to levels comparable to what was found for the TNF-/- mice, the p55-/- N13 mice were as resistant as control C57BL/6 mice (P > 0.05). The incidence of fatal HSE was significantly increased by in vivo neutralization of TNF using soluble TNFR1 (sTNFR1) or depletion of macrophages in C57BL/6 mice (P = 0.0038 and P = 0.0071, respectively). Strikingly, in vivo neutralization of TNF in HSV-1-infected p55-/- p75-/- mice by use of three independent approaches (treatment with soluble p55 receptor, anti-TNF monoclonal antibody, or in vivo small interfering RNA against TNF) resulted in significantly increased mortality rates (P = 0.005), comparable in magnitude to those for C57BL/6 mice treated with sTNFR1 (P = 0.0018). Overall, these results indicate that while TNF is required for resistance to fatal HSE, both p55 and p75 receptors are dispensable. Precisely how TNF mediates protection against HSV-1 mortality in p55-/- p75-/- mice remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17108044      PMCID: PMC1797509          DOI: 10.1128/JVI.02243-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  73 in total

Review 1.  The TNF and TNF receptor superfamilies: integrating mammalian biology.

Authors:  R M Locksley; N Killeen; M J Lenardo
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

2.  Antiviral activity of tumor necrosis factor is signaled through the 55-kDa type I TNF receptor [corrected].

Authors:  G H Wong; L A Tartaglia; M S Lee; D V Goeddel
Journal:  J Immunol       Date:  1992-11-15       Impact factor: 5.422

3.  Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking TNF.

Authors:  P Wilhelm; U Ritter; S Labbow; N Donhauser; M Röllinghoff; C Bogdan; H Körner
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

4.  Interferon (IFN)-gamma and Herpes simplex virus/tumor necrosis factor-alpha synergistically induce nitric oxide synthase 2 in macrophages through cooperative action of nuclear factor-kappa B and IFN regulatory factor-1.

Authors:  S R Paludan; L Malmgaard; S Ellermann-Eriksen; L Boscá; S C Mogensen
Journal:  Eur Cytokine Netw       Date:  2001 Apr-Jun       Impact factor: 2.737

5.  Lymphotoxin alpha-/- mice develop functionally impaired CD8+ T cell responses and fail to contain virus infection of the central nervous system.

Authors:  U Kumaraguru; I A Davis; S Deshpande; S S Tevethia; B T Rouse
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

Review 6.  TNF and TNFR biology in health and disease.

Authors:  M F McDermott
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2001-06       Impact factor: 1.770

7.  Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages.

Authors:  G Eissner; S Kirchner; H Lindner; W Kolch; P Janosch; M Grell; P Scheurich; R Andreesen; E Holler
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

8.  Specific induction of 80-kDa tumor necrosis factor receptor shedding in T lymphocytes involves the cytoplasmic domain and phosphorylation.

Authors:  P D Crowe; T L VanArsdale; R G Goodwin; C F Ware
Journal:  J Immunol       Date:  1993-12-15       Impact factor: 5.422

9.  Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection.

Authors:  K Pfeffer; T Matsuyama; T M Kündig; A Wakeham; K Kishihara; A Shahinian; K Wiegmann; P S Ohashi; M Krönke; T W Mak
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

10.  Neutrophil-mediated suppression of virus replication after herpes simplex virus type 1 infection of the murine cornea.

Authors:  T M Tumpey; S H Chen; J E Oakes; R N Lausch
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

View more
  37 in total

Review 1.  Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Authors:  Pauline L Martin; Peter J Bugelski
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Effects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccines.

Authors:  Michael Luong; Jennifer S Lam; Jianmin Chen; Stuart M Levitz
Journal:  Vaccine       Date:  2007-03-30       Impact factor: 3.641

3.  Microglia and a functional type I IFN pathway are required to counter HSV-1-driven brain lateral ventricle enlargement and encephalitis.

Authors:  Christopher D Conrady; Min Zheng; Nico van Rooijen; Douglas A Drevets; Derek Royer; Anthony Alleman; Daniel J J Carr
Journal:  J Immunol       Date:  2013-02-04       Impact factor: 5.422

4.  The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.

Authors:  W Hans Meisen; Eric S Wohleb; Alena Cristina Jaime-Ramirez; Chelsea Bolyard; Ji Young Yoo; Luke Russell; Jayson Hardcastle; Samuel Dubin; Kamaldeen Muili; Jianhua Yu; Michael Caligiuri; Jonathan Godbout; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2015-03-31       Impact factor: 12.531

Review 5.  Manipulation of apoptosis and necroptosis signaling by herpesviruses.

Authors:  Hongyan Guo; William J Kaiser; Edward S Mocarski
Journal:  Med Microbiol Immunol       Date:  2015-04-01       Impact factor: 3.402

6.  A single-amino-acid substitution in herpes simplex virus 1 envelope glycoprotein B at a site required for binding to the paired immunoglobulin-like type 2 receptor alpha (PILRalpha) abrogates PILRalpha-dependent viral entry and reduces pathogenesis.

Authors:  Jun Arii; Jing Wang; Tomomi Morimoto; Tadahiro Suenaga; Hiroomi Akashi; Hisashi Arase; Yasushi Kawaguchi
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

7.  Targeted delivery of siRNA to macrophages for anti-inflammatory treatment.

Authors:  Sang-Soo Kim; Chunting Ye; Priti Kumar; Isaac Chiu; Sandesh Subramanya; Haoquan Wu; Premlata Shankar; N Manjunath
Journal:  Mol Ther       Date:  2010-03-09       Impact factor: 11.454

8.  Herpes Encephalitis: A Mortal Complication in a Patient Treated with Immunosuppressive Drugs because of Immune-Related Adverse Events after Ipilimumab Treatment.

Authors:  Lieke van Montfort; Caroline M Loos; Monique Anten; Rob L H Jansen
Journal:  Case Rep Oncol       Date:  2017-12-18

9.  Effector CD4+ T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords.

Authors:  Alison J Johnson; Chin-Fun Chu; Gregg N Milligan
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

10.  Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model.

Authors:  Kenneth A Howard; Søren R Paludan; Mark A Behlke; Flemming Besenbacher; Bent Deleuran; Jørgen Kjems
Journal:  Mol Ther       Date:  2008-09-30       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.